Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fetal echocardiography has allowed prenatal diagnosis of heart disease to become a reality over the last decade. Recently, pulsed Doppler flow studies have been applied to the examination of the fetal cardiovascular system. In fetuses with dysrhythmias, complex structural heart malformations, nonimmune hydrops fetalis, or mothers receiving nonsteroidal prostaglandin synthetase inhibitors, pulsed Doppler echocardiographic studies are clinically indicated. These studies involve noninvestigational tests that provide information of critical clinical import. These studies may occasionally, require energy intensities that exceed the 510(k) limits. The physician should be held responsible for educating patients to the potential risks versus benefits of any imaging study they undergo, but appending potentially alarming labels to transducers, machines, or cathode-ray tube displays can only serve to undermine the fabric of the physician-patient relationship without achieving the desired goal of protection of the patient.
 ...
PMID:Doppler echocardiography in the human fetus. 307 53

Either continued patency or closure of the ductus arteriosus is needed to improve survival of infants with certain kinds of congenital heart disease. In many of these infants, the use of prostaglandin (PGE1) or a prostaglandin synthetase inhibitor (indomethacin) permits clinical stabilization in preparation for surgery or makes surgery unnecessary. Although these forms of therapy carry some risk, the risk does not outweigh that of the untreated congenital defects.
 ...
PMID:Prostaglandins and the management of congenital heart disease. 689 Jul 58

In congenital heart disease with left- or right-sided obstruction, prostaglandin E (PGE)1 or PGE2 is infused to maintain ductus arteriosus (DA) patency. We hypothesized that transfection of the DA with PGE synthase would lead to a greater production of PGE2 in situ and, hence, patency of the DA. The cDNA for human prostaglandin synthase was sequenced and ligated into a eukaryotic expression vector. The negative control was created by ligating the cDNA encoding the bacterial protein chloramphenicol acetyltransferase into the same plasmid. Transfection (600 microg DNA) was achieved in lambs within the first 24 h of life using the hemagglutinating virus of Japan (HVJ)-liposome transfection method with a custom-made, basket-weave-perforated catheter. Echocardiography was performed to assess DA patency until the time of sacrifice. To confirm expression of the transgene, PGE2 concentration was measured in organ culture of the DA by immunoassay and by Western immunoblotting of homogenized DA tissue. Patency of the DA was demonstrated by color Doppler in all the lambs (7/7) in which the PGE synthase was delivered, whereas functional closure was seen in the control group (6/6). The PGE2 concentration in the culture medium of the explanted DA in the treatment group was 3-fold higher than that of the control groups. Western immunoblotting confirmed the presence of PGE synthase in the treatment group. Gene transfer of PGE synthase to the DA is feasible and will maintain patency for at least 1 wk.
 ...
PMID:Gene transfer of prostaglandin synthase maintains patency of the newborn lamb arterial duct. 1618 5